文献速递心力衰竭与心肌病

利奥西呱治疗肺动脉高压合并射血分数保留心衰:haemoDYNAMIC试验

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
PubMed 文献 · Eur Heart J · 2022-01-01

该IIb期随机双盲安慰剂对照多中心试验评估口服可溶性鸟苷酸环化酶刺激剂利奥西呱在肺动脉高压合并射血分数保留心衰(PH-HFpEF)患者中的疗效。P=0.0142)。利奥西呱改善血流动力学,多数患者安全,但因药物相关不良事件退出更多,研究期间未改变临床症状。

要点

  • 利奥西呱可改善PH-HFpEF患者静息心输出量
  • 26周内未观察到临床症状改善
  • 药物相关不良事件导致退出增多,但无相关严重不良事件或死亡

核心结论

  • 利奥西呱改善了PH-HFpEF患者的血流动力学,但未改变临床症状,且药物相关不良事件导致更多退出。

研究设计与样本

  • IIb期随机双盲安慰剂对照平行组多中心试验,在奥地利和德国5家医院招募患者。
  • 关键入选标准:平均肺动脉压≥25 mmHg、肺动脉楔压>15 mmHg、左心室射血分数≥50%。
  • 患者按1:1随机接受口服利奥西呱或安慰剂,起始0.5 mg每日三次,上调至1.5 mg每日三次。
  • 主要疗效终点为基线至第26周静息心输出量变化,通过右心导管测量,采用全分析集分析。

主要发现

  • 26周时利奥西呱组心输出量增加0.37±1.263 L/min,安慰剂组下降-0.11±0.921 L/min。
  • 最小二乘均值差为0.54 L/min(95%CI 0.112,0.971;P=0.0142)。
  • 5例患者因利奥西呱相关不良事件退出,但无利奥西呱相关严重不良事件或死亡。

临床怎么用

  • 利奥西呱可用于改善PH-HFpEF患者的血流动力学,但需注意药物相关不良事件及退出风险。
  • 研究期间未观察到临床症状改善,不应以改善症状为治疗目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF). To date, neither established heart failure therapies nor pulmonary vasodilators proved beneficial. This study investigated the efficacy of chronic treatment with the oral soluble guanylate cyclase stimulator riociguat in patients with PH-HFpEF. METHODS AND RESULTS: The phase IIb, randomized, double-blind, placebo-controlled, parallel-group, multicentre DYNAMIC trial assessed riociguat in PH-HFpEF. Patients were recruited at five hospitals across Austria and Germany. Key eligibility criteria were mean pulmonary artery pressure ≥25 mmHg, pulmonary arterial wedge pressure >15 mmHg, and left ventricular ejection fraction ≥50%. Patients were randomized to oral treatment with riociguat or placebo (1:1). Patients started at 0.5 mg three times daily (TID) and were up-titrated to 1.5 mg TID. The primary efficacy endpoint was change from baseline to week 26 in cardiac output (CO) at rest, measured by right heart catheterization. Primary efficacy analyses were performed on the full analysis set. Fifty-eight patients received riociguat and 56 patients placebo. After 26 weeks, CO increased by 0.37 ± 1.263 L/min in the riociguat group and decreased by -0.11 ± 0.921 L/min in the placebo group (least-squares mean difference: 0.54 L/min, 95% confidence interval 0.112, 0.971; P = 0.0142). Five patients dropped out due to riociguat-related adverse events but no riociguat-related serious adverse event or death occurred. CONCLUSION: The vasodilator riociguat improved haemodynamics in PH-HFpEF. Riociguat was safe in most patients but led to more dropouts as compared to placebo and did not change clinical symptoms within the study period.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Dachs, Duca, Rettl, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J. 2022. PMID: 35909264. doi:10.1093/eurheartj/ehac389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。